C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 86, Issue 1, Pages 75-85
Publisher
Springer Science and Business Media LLC
Online
2020-06-14
DOI
10.1007/s00280-020-04088-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current status of prognostic factors in patients with metastatic renal cell carcinoma
- (2019) Jun Teishima et al. INTERNATIONAL JOURNAL OF UROLOGY
- Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer—A protocol for systematic review and meta-analysis
- (2019) Chellan Kumarasamy et al. MEDICINE
- Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
- (2019) Hiroki Ishihara et al. Targeted Oncology
- C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab
- (2019) Kotaro Suzuki et al. International Journal of Clinical Oncology
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cachectic Cancer Patients: Immune to Check-point Inhibitor Therapy?
- (2018) Christopher C Coss et al. CLINICAL CANCER RESEARCH
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor
- (2018) Norikazu Matsuo et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
- (2017) Markus V. Heppt et al. EUROPEAN JOURNAL OF CANCER
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
- (2017) Jun Teishima et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis
- (2017) Jie-Hui Zhong et al. Oncotarget
- Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
- (2017) Yuko Oya et al. Oncotarget
- Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
- (2017) Ghayathri Jeyakumar et al. Journal for ImmunoTherapy of Cancer
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma
- (2015) Jun Teishima et al. BJU INTERNATIONAL
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy
- (2012) Hiroki Ito et al. BMC CANCER
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
- (2012) Donald C. McMillan CANCER TREATMENT REVIEWS
- Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
- (2011) Kristine H. Allin et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients
- (2009) Sei Naito et al. EUROPEAN UROLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Absolute Preoperative C-Reactive Protein Predicts Metastasis and Mortality in the First Year Following Potentially Curative Nephrectomy for Clear Cell Renal Cell Carcinoma
- (2009) T.V. Johnson et al. JOURNAL OF UROLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma
- (2008) Kazutaka Saito et al. EUROPEAN UROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started